Literature DB >> 23959409

Phlegmasia caerulea dolens secondary to pelvic plasmacytoma and left femoral deep vein thrombosis.

Brett Doleman1, Kumar Abayasekara, James Kirk.   

Abstract

INTRODUCTION: Phlegmasia caerulea dolens (PCD) is a clinical syndrome caused by venous obstruction leading to peripheral limb ischaemia. It can ultimately lead to venous gangrene, amputation or death in 25% of cases. PRESENTATION OF CASE: A 52-year-old man with a background of myeloma developed PCD secondary to an obstructing plasmacytoma and left femoral vein deep vein thrombosis (DVT). These were treated with combined radiotherapy and anticoagulation, with resolution of the patient's symptoms. His recovery was complicated by the development of heparin-induced thrombocytopenia (HIT) and cutaneous vasculitis. DISCUSSION: Both plasmacytoma and DVT are recognised complications of myeloma. This is, to our knowledge, the first description of these phenomena in combination causing PCD. The combination of venous stasis from the obstructing plasmacytoma and hypercoagulability from the underlying myeloma may have contributed to clot formation. A multifaceted treatment approach was required which aimed at improving venous flow via radiotherapy to the plasmacytoma and dissolving the obstructing clot with anticoagulant therapy.
CONCLUSION: PCD has a high mortality and morbidity. Recognition is important to avoid an incorrect diagnosis of arterial occlusion and inappropriate surgical intervention. Treatment must be focused on removing the offending causes.
Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Deep vein thrombosis; Myeloma; Phlegmasia caerulea dolens

Year:  2013        PMID: 23959409      PMCID: PMC3785849          DOI: 10.1016/j.ijscr.2013.07.010

Source DB:  PubMed          Journal:  Int J Surg Case Rep        ISSN: 2210-2612


  7 in total

1.  Intravenous thrombolytic therapy in patients with phlegmasia caerulea dolens.

Authors:  Bernard Tardy; Nathalie Moulin; Patrick Mismetti; Hervé Decousus; Silvy Laporte
Journal:  Haematologica       Date:  2006-02       Impact factor: 9.941

Review 2.  Phlegmasia caerulea dolens and venous gangrene.

Authors:  J M Perkins; T R Magee; R B Galland
Journal:  Br J Surg       Date:  1996-01       Impact factor: 6.939

3.  Phlegmasia caerulea dolens and venous gangrene.

Authors:  A Mahomed; D Williams
Journal:  Br J Surg       Date:  1996-08       Impact factor: 6.939

4.  Oral rivaroxaban for symptomatic venous thromboembolism.

Authors:  Rupert Bauersachs; Scott D Berkowitz; Benjamin Brenner; Harry R Buller; Hervé Decousus; Alex S Gallus; Anthonie W Lensing; Frank Misselwitz; Martin H Prins; Gary E Raskob; Annelise Segers; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Henri Bounameaux; Alexander Cohen; Bruce L Davidson; Franco Piovella; Sebastian Schellong
Journal:  N Engl J Med       Date:  2010-12-03       Impact factor: 91.245

5.  Low-dose intra-arterial thrombolysis in the treatment of phlegmasia caerulea dolens.

Authors:  Z K Wlodarczyk; M Gibson; R Dick; G Hamilton
Journal:  Br J Surg       Date:  1994-03       Impact factor: 6.939

Review 6.  The blood coagulation mechanism in multiple myeloma.

Authors:  Maurizio Zangari; Fariba Saghafifar; Paulette Mehta; Bart Barlogie; Louis Fink; Guido Tricot
Journal:  Semin Thromb Hemost       Date:  2003-06       Impact factor: 4.180

7.  Advances in the treatment of phlegmasia cerulea dolens.

Authors:  D B Hood; F A Weaver; J G Modrall; A E Yellin
Journal:  Am J Surg       Date:  1993-08       Impact factor: 2.565

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.